Clinical Trial Detail

NCT ID NCT02119663
Title A Study of Ruxolitinib in Pancreatic Cancer Patients
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements no
Sponsors Incyte Corporation
Indications

pancreatic adenocarcinoma

Therapies

Capecitabine

Ruxolitinib + Capecitabine

Age Groups: adult

No variant requirements are available.